MedTrace Logo

Dextroamphetamine as an Adjunct in Cocaine Treatment - 1

NCT00000304 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2017-01-12

No results posted yet for this study

Summary

The purpose of this study is to evaluate dextroamphetamine sulfate (sustained release) as an adjunct in cocaine treatment; an evaluation of the ""replacement"" strategy.

Conditions

  • Cocaine-Related Disorders
  • Substance-Related Disorders

Interventions

DRUG

Dextroamphetamine

15 mg for first 8 weeks and 30 mg for 2nd 8 weeks

DRUG

D-Amphetamine

30 mg for the first 8 weeks and 60 for the second 8 weeks (16 weeks total)

DRUG

Placebo

Placebo

Sponsors & Collaborators

  • University of Texas

    collaborator OTHER

  • National Institute on Drug Abuse (NIDA)

    lead NIH

Principal Investigators

  • John Grabowski, Ph.D. · University of Texas

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1997-08-31
Primary Completion
2001-08-31
Completion
2001-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00000304 on ClinicalTrials.gov